Skip to content

Return to Work in Patients With Chronic Pain

Vocational Rehabilitation and Return to Work in Patients With Chronic Pain: a Randomised Controlled Trial

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03827174
Acronym
UWORKin
Enrollment
8
Registered
2019-02-01
Start date
2019-08-14
Completion date
2021-02-01
Last updated
2023-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Endometriosis

Keywords

Chronic pain, Endometriosis, Opioid therapy, Return to work, Vocational rehabilitation, Behavioural medicine

Brief summary

This study aims to evaluate whether a vocational behaviour change ability programme has any additional effect on return to work compared with return to work coordination only in persons with chronic pain.

Detailed description

New vocational rehabilitation models including the workplace are urgently needed for persons with chronic pain. Return to work coordination means external and internal coordination regarding sick leave by help of a rehabilitation coordinator from health care. The goal is to establish a common return to work plan between employer and employee as dictated by Swedish law. The hypothesis is that return to work coordination is not sufficient. Additional effects on return to work and work ability from a behaviour change ability programme aiming to enhance work ability by targeting context at the workplace, physical and psychological functioning, and behavioral skills at work are expected. The hypothesis is tested in a randomised controlled trial. Before the start of the trial a series of 3-6 experimental single case studies will be performed to study the implementation of the interventions more thoroughly.

Interventions

OTHERReturn To Work Coordination

External and internal coordination regarding sick leave. Establishment of a common return to work plan between employer och employee.

BEHAVIORALBehaviour Change Ability Program

1. Return to work coordination 2. Education for employers and employees in pain neuroscience, validation and problem-solving. 3. Patient-specific goal setting for return to work 4. Exercise and behavioural skills training related to return to work

Sponsors

Uppsala University Hospital
CollaboratorOTHER
AFA Insurance
CollaboratorINDUSTRY
The Swedish Research Council
CollaboratorOTHER_GOV
Uppsala County Council, Sweden
CollaboratorOTHER_GOV
Uppsala University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

The outcomes assessors are blinded to study condition during all measurements. Participants and providers of the return to work coordination intervention are blinded until a rehabilitation plan has been completed. Thereafter allocation to study condition is disclosed and the other components of the behaviour change ability programme are provided to those in the experimental group.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Chronic pain with a duration for more than 3 months * On sick-leave 25%-100% from salaried employment or studies, for at least 30 days * Identified employer or director of studies * Ability to understand, speak, and write Swedish

Exclusion criteria

* Severe substance use disorder * Severe psychiatric illness * Recruited participants with employers who does not consent to participate

Design outcomes

Primary

MeasureTime frameDescription
Work ability12 monthsSelf-report. Work Ability Index (WAI). The questionnaire covers 7 dimensions: 1. current work ability compared with lifetime best 2. work ability in relation to the demands of the job 3. number of diagnosed illnesses or limiting conditions 4. estimated impairment owing to diseases/illnesses or limiting conditions 5. amount of sick leave during the last year 6. prognosis of work ability in 2 years' time 7. psychological resources. The dimensions have different scores. A total index is computed ranging from 7 to 49, where higher scores indicate higher work ability.
Return to workNumber of days during a 12-month period from baseline to 12 months post baseline.Average sick leave according to the Swedish Social Insurance registry, defined as net days.

Secondary

MeasureTime frameDescription
Return to workBaseline, 6 months, 24 monthsAverage sick leave according to the Swedish Social Insurance registry, defined as net days.
Short-term sick leave < 2 weeks, number of days6 months, 12 months, 24 monthsSelf-reported number of days with sick-leave not exceeding two weeks
Health-related quality of life: EQ-5DBaseline, 6 months, 12 months, 24 monthsSelf-report. The EuroQoL - Five dimension (EQ-5D). The five dimensions are: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each scales ranges from 0 to 2, where a low score indicates better health. The EQ-5D questionnaire also includes a visual analog scale where perceived health status is rated with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).
Opioid useBaseline, 6 months, 12 months, 24 monthsInterview: Time-Line-Follow-Back. 4-week recall regarding opioid medication yes/no and dose.
Substance use disorderBaseline, 6 months, 12 months, 24 monthsInterview: Mini International Neuropsychiatric Interview, Part J (Substance use). Response format yes/no. Mild substance use disorder = 2-3 symptoms Moderate substance use disorder = 4-5 symptoms Severe substance use disorder = 6 or more symptoms
Pain severity: The Brief Pain InventoryBaseline, 6 months, 12 months, 24 monthsSelf-report. The Brief Pain Inventory. Severity is measured with 4 items where worst, least, average, and current pain during the past week are scored. Each scale ranges from 0-10, where 0 = 'no pain' and 10 = 'pain as bad as can be'. Each of the severity scales will be presented separately.
Pain interference: The Brief Pain InventoryBaseline, 6 months, 12 months, 24 monthsSelf-report. The Brief Pain Inventory. Interference is measured with 7 items (general activity, mood, working ability, normal work, relations with other people, sleep, and enjoyment of life). Each scale ranges from 0 to 10, where 0 ='does not interfere', and 10 = 'completely interferes'. Interference is scored as the mean of the seven interference items. Higher scores indicate higher pain interference.
BalanceBaseline, 6 months, 12 monthsThe MiniBESTest
Functional lifting capacityBaseline, 6 months, 12 monthsProgressive Isoinertial Lifting Evaluation (PILE): cervical lifting test
Grip strengthBaseline, 6 months, 12 monthsDynamometer GRIPPIT (name of brand)
Work AbilityBaseline, 6 months, 24 monthsSelf-report. Work Ability Index (WAI). The questionnaire covers 7 dimensions: 1. current work ability compared with lifetime best 2. work ability in relation to the demands of the job 3. number of diagnosed illnesses or limiting conditions 4. estimated impairment owing to diseases/illnesses or limiting conditions 5. amount of sick leave during the last year 6. prognosis of work ability in 2 years' time 7. psychological resources The dimensions have different scores. A total index is computed ranging from 7 to 49, where higher scores indicate higher work ability.
SleepBaseline, 6 months, 12 monthsSleep pattern: Actigraph during night and days for one week.
Global goal achievement6 months, 12 months, 24 monthsSelf-report. Patient global impression of change (PGIC). The measure reflects participant's beliefs about the efficacy of treatment. The patient rates overall improvement on a 7-point scale where 3 = 'very much improved', 2 = 'much improved', 1 = 'minimally improved', 0 = 'no change', -1 = 'minimally worse', -2 = 'much worse', and -3 ='very much worse'.
Explorative identification of change in biomarkersChanges from baseline to 6 months.Biomarkers will be explored by use of the OLINK (name of brand) panel which enables analysis of 92 inflammation-related protein biomarkers.
CatastrophizingBaseline, 6 months, 12 monthsSelf-report, The Pain Catastrophizing Scale (PCS) - Swedish version. 13 items, ranging from 0 to 4 where 0 = 'not at all', 4 = 'all the time'. A total score is calculated ranging from 0 to 52 where higher scores indicate higher catastrophizing.
Fear of movement and reinjuryBaseline, 6 months, 12 monthsSelf-report, The Tampa Scale of Kinesiophobia-11 (TSK-11), Swedish version. 11 items ranging from 1 to 4 where 1 = 'does not agree at all', 4 = 'totally agree'. A total score is calculated ranging from 11 to 44 where higher scores indicate higher fear of movement/kinesiophobia.
Psychological inflexibility in painBaseline, 6 months, 12 monthsSelf-report. Psychological inflexibility in pain (PIPS) is a 12-item scale used to assess psychological inflexibility (i.e. avoidance, acceptance, fusion, values orientation, dirty discomfort) in people with chronic pain. Two main components are measured: 1) Avoidance of pain (items: 1,2,4,5,7,8,10,11), 2) Fusion with pain thoughts (items: 3,6,9,12) Scoring: Respondents are asked to rate items on a 7-point scale that ranges from 1= 'never true' to 7 = 'always true'. Scores are summed to a total score and to two subscale scores. Higher scores indicate greater levels of psychological inflexibility.
Depressive symptomsBaseline, 6 months, 12 months, 24 monthsSelf-report: Patient Health Questionnaire - 9 (PHQ-9), Swedish version. 9 items ranging from 0 ='not at all', to 3 ='almost every day'. 1 item ranging from 0 ='no difficulties, to 3 = 'extreme difficulties'. The first 9 items are summed to a sum score ranging from 0 to 27, where: 0-4 = no signs of depression, 5-9 = mild depression, 10-14 = moderate depression, 15-19 = moderately severe depression, 20-27 = severe depression. Item 10 is reported as a single item where high scores indicate high interference with daily function.
Generalised Anxiety DisorderBaseline, 6 months, 12 months, 24 monthsSelf-report: Generalised Anxiety Disorder (GAD-7). 7 items ranging from 0 ='not at all', to 3 ='almost every day'. 1 item ranging from 0 ='no difficulties, to 3 = 'extreme difficulties'. 1 item ranging from 0 ='not at all, to 3 = 'very disturbing'. The first 7 items are summed to a sum score ranging from 0 to 21, where: 0-4 = no signs of anxiety, 5-9 = mild GAD, 10-14 = moderate GAD, 15-21 = severe GAD. Item 8 is reported as a single item where higher score means higher interference.
Experience of injusticeBaseline, 6 months, 12 monthsSelf-report: Injustice Experience Questionnaire (IEQ), Swedish version. 12 items ranging from 0 ='never, to 4 ='all the time'. A total score is computed by summing the scores to all 12 items, ranging from 0-48 where higher scores indicate higher experience of injustice. Two subscales is used. 1) Blame/unfairness by summing items 3, 7, 9, 10, 11, 23. 2\) Severity/irreparability by summing 1, 2, 4, 5, 6, 8.
Cognitive functionBaseline, 6 months, 12 monthsThe Cambridge Neuropsychological Test Automated Battery (CANTAB): Spatial Working Memory, Paired Associates Learning, Delayed Match to Sample and Stocking of Cambridge (SOC).
Physical activity levelBaseline, 6 months, 12 monthsAccelerometer during one week. Time spent in sedentary, low, moderate and vigorous physical activity.

Other

MeasureTime frameDescription
Patient-specific goals for return to workBaseline, 6 months, 12 monthsPatient Goal Priority Questionnaire (PGPQ-WORK). Patient-specific questionnaire where the participant list 1-3 work-related activities that he or she wish to be able to perform better as a result of treatment. Activity, self-efficacy, fear of performance, and expected outcome level is then rated for each activity separately on 4 11-point numerical rating scales where higher scores indicate worse outcomes.
Self-efficacy to support return to work (employer): Number of itemsBaseline, 6 monthsStudy specific questions regarding the employer's self-efficacy to support the employee to return to work. Number of items is tied to individual process analysis of what is required to return to work in each specific case.
Number of participants who report adverse events associated with treatmentUp to 6 monthsAdverse events will be measured with a study-specific diary including a check-list and open ended questions.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026